The impact of statin use on disease-related symptoms in patients with chronic myeloproliferative neoplasms

go back to reference Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA (2012) Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 30(33):4098–4103CrossRefPubMedPubMedCentral Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA (2012) Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 30(33):4098–4103CrossRefPubMedPubMedCentral

go back to reference Griner LN, McGraw KL, Johnson JO, List AF, Reuther GW (2013) JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth. Br J Haematol 160(2):177–187CrossRefPubMed Griner LN, McGraw KL, Johnson JO, List AF, Reuther GW (2013) JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth. Br J Haematol 160(2):177–187CrossRefPubMed

go back to reference Krečak I, Holik H, Morić-Perić M, Zekanović I, Coha B, Gverić-Krečak V (2020) The impact of statins on the intensity of phlebotomies in polycythemia vera. Ann Hematol 99(4):911–912CrossRefPubMed Krečak I, Holik H, Morić-Perić M, Zekanović I, Coha B, Gverić-Krečak V (2020) The impact of statins on the intensity of phlebotomies in polycythemia vera. Ann Hematol 99(4):911–912CrossRefPubMed

go back to reference Tuyet Kristensen D, Kisbye Øvlisen A, Hjort Kyneb Jakobsen L, Tang Severinsen M, Hannig LH, Starklint J, Hagemann Hilsøe M, Pommer Vallentin A, Brabrand M, Hasselbalch HC, El-Galaly TC, Stidsholt Roug A (2023) Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study. Blood Adv 7(14):3450–3457CrossRefPubMedPubMedCentral Tuyet Kristensen D, Kisbye Øvlisen A, Hjort Kyneb Jakobsen L, Tang Severinsen M, Hannig LH, Starklint J, Hagemann Hilsøe M, Pommer Vallentin A, Brabrand M, Hasselbalch HC, El-Galaly TC, Stidsholt Roug A (2023) Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study. Blood Adv 7(14):3450–3457CrossRefPubMedPubMedCentral

go back to reference Podoltsev NA, Wang R, Shallis RM, Stempel JM, Di M, Neparidze N, Zeidan AM, Huntington SF, Giri S, Hull SC, Gore SD, Ma X (2023) Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer Med 12(18):18889–18900CrossRefPubMedPubMedCentral Podoltsev NA, Wang R, Shallis RM, Stempel JM, Di M, Neparidze N, Zeidan AM, Huntington SF, Giri S, Hull SC, Gore SD, Ma X (2023) Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer Med 12(18):18889–18900CrossRefPubMedPubMedCentral

go back to reference Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245–1251CrossRefPubMed Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245–1251CrossRefPubMed

go back to reference Hasselbalch HC, Riley CH (2006) Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential? Leuk Res 30(10):1217–1225CrossRefPubMed Hasselbalch HC, Riley CH (2006) Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential? Leuk Res 30(10):1217–1225CrossRefPubMed

go back to reference Lukas PS, Krummenacher R, Biasiutti FD, Begré S, Znoj H, von Känel R (2009) Association of fatigue and psychological distress with quality of life in patients with a previous venous thromboembolic event. Thromb Haemost 102(6):1219–1226CrossRefPubMed Lukas PS, Krummenacher R, Biasiutti FD, Begré S, Znoj H, von Känel R (2009) Association of fatigue and psychological distress with quality of life in patients with a previous venous thromboembolic event. Thromb Haemost 102(6):1219–1226CrossRefPubMed

go back to reference Mollon L, Bhattacharjee S (2017) Health related quality of life among myocardial infarction survivors in the United States: a propensity score matched analysis. (Health Qual Life Outcomes 15(1):235CrossRefPubMedPubMedCentral Mollon L, Bhattacharjee S (2017) Health related quality of life among myocardial infarction survivors in the United States: a propensity score matched analysis. (Health Qual Life Outcomes 15(1):235CrossRefPubMedPubMedCentral

go back to reference Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA (2017) Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica 102(1):85–93CrossRefPubMedPubMedCentral Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA (2017) Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica 102(1):85–93CrossRefPubMedPubMedCentral

go back to reference Tefferi A, Hudgens S, Mesa R, Gale RP, Verstovsek S, Passamonti F, Cervantes F, Rivera C, Tencer T, Khan ZM (2014) Use of the Functional Assessment of Cancer therapy–anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. Clin Ther 36(4):560–566CrossRefPubMed Tefferi A, Hudgens S, Mesa R, Gale RP, Verstovsek S, Passamonti F, Cervantes F, Rivera C, Tencer T, Khan ZM (2014) Use of the Functional Assessment of Cancer therapy–anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. Clin Ther 36(4):560–566CrossRefPubMed

go back to reference Bełtowski J, Wójcicka G, Jamroz-Wiśniewska A (2009) Adverse effects of statins - mechanisms and consequences. Curr Drug Saf 4(3):209–228 Bełtowski J, Wójcicka G, Jamroz-Wiśniewska A (2009) Adverse effects of statins - mechanisms and consequences. Curr Drug Saf 4(3):209–228